Upcoming
Future-Proof Your Strategy. New Intelligence Subscriptions Arriving Soon! Schedule a demo! 

Capecitabine Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: November 2024 || SKU: PH7872 || Author: Umesh
excelpdfpowerpoint
180 pages
Report Summary
Table of Contents
List of Tables & Figures
Get Free Sample

Get Expert Insights on Capecitabine Market

Talk to analy

Global Capecitabine Market By Indication (Breast cancer, Colorectal cancer, Gastric cancer, Pancreatic cancer, Others), By Synthesis Type (Chemical-based API, Biological API, Highly potent API (HPAPI)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

 

Capecitabine Market Overview

The global Capecitabine market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including bowel cancer. Capecitabine is a type of chemotherapy called an anti-metabolite. The body changes capecitabine into a common chemotherapy drug called fluorouracil. It stops cells from making and repairing DNA Open a glossary item Cancer cells need to make and repair DNA so they can grow and multiply.

Capecitabine Market Scope

MetricsDetails
CAGRYY%
Market Size Available for Years2022-2031
Estimation Forecast Period2024-2031
Revenue UnitsValue (US$ Mn) 
Segments CoveredIndication, Synthesis Type, Distribution Channel
Regions CoveredNorth America, Europe, Asia-Pacific, South America, and Middle East & Africa
Largest RegionNorth America
Fastest Growing RegionAsia-Pacific
Report Insights CoveredCompetitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights.

 

For more details on this reportRequest for Sample

 

Capecitabine Market Dynamics

Rise in the prevalence of cancers

Cancer is a global health challenge with a rising incidence, driven by factors like ageing populations, lifestyle changes, environmental changes, and increased screening efforts. This leads to a larger pool of patients requiring treatment, increasing the demand for cancer drugs like capecitabine. The industry gains are influenced by this trend, highlighting the need for effective cancer prevention and treatment strategies.

For instance, according to the American Cancer Society, Inc., around 1.9 million new cancer cases are expected to be diagnosed in the U.S. in 2023, and approximately 609,820 cancer-related fatalities in the U.S. in 2023, which is about 1,670 deaths per day.

Furthermore, the global capecitabine market is also driven by various other factors like, advancements in treatment options for cancers, a rise in demand for the drug and others help the market to grow during the forecast period.

Side effects associated with the drug

The global capecitabine market is hampered by various factors in that side effects associated with drugs are one of the factors which include bone marrow suppression, diarrhea, nausea, vomiting, hand-foot syndrome, fatigue, weakness, headache, dizziness, insomnia, paresthesias, abdominal pain, stomatitis, and rashes. Also, other factors like the high cost for manufacturing of capecitabine and others hinder the market during the forecast period.

Capecitabine Market Segmentation

The global capecitabine market is segmented based on indication, synthesis type, distribution channel and region.

The breast cancer from the indication segment accounted for approximately 42.1% of the Capecitabine market share

The breast cancer from the indication segment accounted for approximately 42.1%. In triple-negative breast cancers, adding capecitabine concurrently with standard chemotherapy has been shown to reduce the risk of recurrence but substantially increase treatment toxicity without consistent improvements in overall survival. Breast cancer segment is expected to lead highest market share owing to the factors like, rise in prescriptions of capecitabine, FDA clearance, novel product launches and others help the segment to grow during the forecast period.

For instance, in April 2023, OnQuality Pharmaceuticals  a targeted oncology supportive therapy company developing innovative medications to address unmet needs in oncodermatology and oncogastroenterology and to improve the quality of life for patients receiving anticancer medications, stated that the U.S. Food and Drug Administration (FDA) has cleared our Investigational New Drug (IND) application for OQL036, a potential prophylactic treatment for capecitabine-induced hand-foot syndrome (HFS).

Moreover, Shilpa Medicare announced that it has introduced Capecitabine (Capebel) dispersible tablet (DT) with technology of faster dispersion within 90 seconds to treat colorectal and metastatic breast cancer.

Capecitabine Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to the factors rising prevalence of the various types of cancer like colorectal cancer, colon cancer in the region, FDA approvals etc. Also, rising incidences of cancer can be due to several factors like physical inactivity, obesity, stress, and a sedentary lifestyle.

For instance, on December 14, 2022, the FDA approved updated labeling for capecitabine tablets (brand name Xeloda) under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for certain older oncology drugs to ensure information is clinically meaningful and scientifically up to date. This is the first drug to receive a labeling update under this pilot program.

Covid 19 Impact Analysis

The COVID-19 pandemic significantly impacted the economy, particularly in early 2020, with the closure of API manufacturing facilities leading to challenges such as reduced operational capacity, supply chain disruptions, and difficulties in sourcing raw materials and packaging materials. However, in the latter half of 2020, the demand for specific pharmaceuticals surged, driving increased demand for APIs used in production. This led to significant growth in the API market, highlighting the ongoing impact of the pandemic on the pharmaceutical industry.

Key Developments

  • In February 2021, Dr. Reddy’s Laboratories Ltd. stated the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda (capecitabine) Tablets approved by the U.S. Food and Drug Administration (USFDA).

Competitive Landscape

The major global players in the market include F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries Ltd, Shilpa Medicare limited, Atom Pharma, Global Calcium, LGM Pharma, Cipla Ltd, Teva Pharmaceuticals, Angel Biogenics Pvt Ltd, Salvavidas Pharma and among others.

Why Purchase the Report?

  • To visualize the global capecitabine market segmentation based on indication , synthesis type, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analysing trends and co-development.
  • Excel data sheet with numerous data points of capecitabine market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global capecitabine market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies
Buy this report
Single User
$4350
Multiple User
$4850
Enterprise User
$7850
Proceed to Buy
  Get Free Sample
  Customize Sample
  Demo Full Report
Chat on WhatsApp
FAQ’s

  • North America the dominating region in the Capecitabine Market

  • The Major key players are F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries Ltd, Shilpa Medicare limited, Atom Pharma, Global Calcium, LGM Pharma, Cipla Ltd, Teva Pharmaceuticals, Angel Biogenics Pvt Ltd, Salvavidas Pharma and among others.
Related Reports
pharmaceuticals iconpharmaceuticals

Gastrointestinal Cancer Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 November 21

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Gastrointestinal Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 February 23

Starting from

$4350

medical-devices iconmedical-devices

Gastrointestinal Stents Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 August 30

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Urothelial Cancer Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 January 19

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Colorectal Cancer Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 December 13

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Breast Cancer Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 June 25

Starting from

$4350

WhatsApp